NASDAQ:CRIS

Curis - CRIS News Today

$0.75

+0.05 (+7.17%)

(As of 09/28/2022 05:07 PM ET)

Add

Compare

Today's Range: $0.68
▼
$0.76
50-Day Range: $0.70
▼
$1.30
52-Week Range: $0.68
▼
$8.20

Volume: 890,104 shs
Average Volume: 2.84 million shs
Market Capitalization: $68.78 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $9.67

Get Curis News Delivered to You Automatically

CRIS Media Mentions By Week

CRIS Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

CRIS
News Sentiment
▼
0.57

0.72
▲
Average
Medical
News Sentiment

CRIS News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

CRIS Articles
This Week
▼
12

3
▲
CRIS Articles
Average Week

Source

Source	Headline
	Why Golden Ocean Group Is Trading Higher By 7%; Here Are 28 Stocks Moving Premarket - Markets Insider markets.businessinsider.com - September 26 at 11:26 AM
	Curis, Inc. Forecasted to Earn FY2022 Earnings of ($0.69) Per Share (NASDAQ:CRIS) americanbankingnews.com - September 23 at 7:56 AM
	Curis' (CRIS) Overweight Rating Reaffirmed at Cantor Fitzgerald americanbankingnews.com - September 23 at 6:28 AM
	KuCoin Announces Partnership with Legend Trading, A Leading Fiat-to-Crypto Payment Gateway - Benzinga benzinga.com - September 22 at 10:18 AM
	Curis Announces Date for the 2nd Annual VISTA Symposium - Yahoo Finance finance.yahoo.com - September 19 at 10:34 PM
	CRIS.A - Curis, Inc. \| Stock Price & Latest News \| Reuters reuters.com - September 18 at 10:38 AM
	Curis To Present At H.C. Wainwright Global Investment Conference; Webcast At 4:00 PM ET - Nasdaq nasdaq.com - September 14 at 7:16 PM
	Curis (CRIS) – Curis to Present at Upcoming Healthcare Conferences in September - Benzinga benzinga.com - September 7 at 9:20 AM
	Curis Says FDS Allows Additional Patient Enrollment For TakeAim Leukemia Study markets.businessinsider.com - August 31 at 5:35 PM
	Curis leukemia study's monotherapy part gets FDA nod to resume enrollment, others still under partial hold seekingalpha.com - August 31 at 5:35 PM
Get the Latest News and Ratings for Your Stocks Enter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter.
	Curis Announces FDA Has Notified Co. It May Resume Enrollment Of Additional Patients In Monotherapy Dose - Benzinga benzinga.com - August 30 at 6:27 PM
	FDA Allows Patient Enrollment to Resume in Monotherapy Dose Escalation of Emavusertib in TakeAim Leukemia Study finance.yahoo.com - August 30 at 12:51 PM
	Curis Resumes Enrollment In Monotherapy TakeAim Leukemia Study, Combo Phase Still Under Partial Hold finance.yahoo.com - August 30 at 12:51 PM
	Curis's Return On Capital Employed Insights - Benzinga benzinga.com - August 24 at 3:40 PM
	Curis (CRIS) Lymphoma Study's Clinical Hold Lifted, Shares Gain finance.yahoo.com - August 19 at 6:20 PM
	Recent uptick might appease Curis, Inc. (NASDAQ:CRIS) institutional owners after losing 82% over the past year - Nasdaq nasdaq.com - August 19 at 1:20 PM
	Analyzing Curis Short Interest By Benzinga - Investing.com UK uk.investing.com - August 19 at 2:07 AM
	Analyzing Curis Short Interest - Benzinga benzinga.com - August 18 at 9:06 PM
	Curis Announces FDA Lifts Partial Clinical Hold On The TakeAim Lymphoma Study Of Emavusertib - Benzinga benzinga.com - August 18 at 4:05 PM
	Thinking about buying stock in Curis, bluebird bio, Nerdy, Sientra, or Aquestive Therapeutics? - Benzinga benzinga.com - August 18 at 4:05 PM
	Why Is Curis (CRIS) Stock Up 20% Today? - InvestorPlace investorplace.com - August 18 at 4:05 PM
	Curis, Allarity top healthcare gainers; Blue Water, Accelerate lead losers' pack - Seeking Alpha seekingalpha.com - August 18 at 11:05 AM
	FDA Lifts Partial Clinical Hold on the TakeAim Lymphoma Study of Emavusertib finance.yahoo.com - August 18 at 11:05 AM
	FDA Clears Curis' Lymphoma Study, Keeping Leukemia Trial Still Stalled benzinga.com - August 18 at 9:55 AM
	Investors in Curis (NASDAQ:CRIS) from five years ago are still down 87%, even after 15% gain this past week finance.yahoo.com - August 13 at 11:18 AM
	Form 3 CURIS INC For: Aug 05 Filed by: Duvall Diantha - StreetInsider.com streetinsider.com - August 10 at 8:07 PM
	Global TIM3 Inhibitors Drug Clinical Trials & Market Opportunities Report 2022: Market to Surpass $1 Bill - Benzinga benzinga.com - August 8 at 10:24 PM
	Curis (CRIS) Q2 2022 Earnings Call Transcript - The Motley Fool fool.com - August 5 at 1:12 PM
	Curis (CRIS) Q2 2022 Earnings Call Transcript finance.yahoo.com - August 5 at 8:12 AM
	Curis (CRIS) Reports Q2 Loss, Tops Revenue Estimates finance.yahoo.com - August 4 at 9:18 PM
Get the Latest News and Ratings for Your Stocks Enter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter.
	Curis Reports Second Quarter 2022 Financial Results and Business Update finance.yahoo.com - August 4 at 4:18 PM
	Curis Q2 2022 Earnings Preview (NASDAQ:CRIS) - Seeking Alpha seekingalpha.com - August 4 at 11:17 AM
	Covid. A Coma. A Stroke. José Parlá Returns From the Edge. - The New York Times nytimes.com - July 31 at 3:56 PM
	Curis Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) finance.yahoo.com - July 29 at 6:04 PM
	Curis to Release Second Quarter 2022 Financial Results and Hold Conference Call on August 4, 2022 - Yahoo Finance finance.yahoo.com - July 28 at 9:35 PM
	Curis to Release Second Quarter 2022 Financial Results and Hold Conference Call on August 4, 2022 finance.yahoo.com - July 28 at 4:35 PM
	6 Penny Stocks With 1,000% Upside Potential - Nasdaq nasdaq.com - July 25 at 11:38 PM
	Coach Eric Nicksick thinks new gym leader Chris Curtis 'playing with house money' at UFC Fight Night 208 - MMA Junkie mmajunkie.usatoday.com - July 22 at 6:05 PM
	Curis: Asymmetric Risk And Reward (NASDAQ:CRIS) - Seeking Alpha seekingalpha.com - July 17 at 5:16 AM
	What Kind Of Shareholders Hold The Majority In Curis, Inc.'s (NASDAQ:CRIS) Shares? finance.yahoo.com - July 8 at 8:34 AM
	The global bio decontamination market is projected to reach USD 227 million by 2027 from USD 159 million in 2022, at a CAGR of 7.3% from 2022 to 2027 - Yahoo Finance finance.yahoo.com - June 29 at 5:17 AM
	Atreca Appoints Stephen Gould, Ph.D. as Chief Scientific Officer - StreetInsider.com streetinsider.com - June 16 at 4:44 PM
	Curis Announces Presentations on Biomarker Development and Emavusertib Clinical Data at the 2022 European Hematology Association (EHA) Hybrid Congress - Yahoo Finance finance.yahoo.com - June 11 at 3:11 AM
	Curis Announces Presentations on Biomarker Development and Emavusertib Clinical Data at the 2022 European Hematology Association (EHA) Hybrid Congress finance.yahoo.com - June 10 at 8:36 AM
	Curis To Present At 2022 Jefferies Global Healthcare Conference; Webcast At 11:00 AM ET - Nasdaq nasdaq.com - June 9 at 4:17 PM
	Celldex to Present at the 2022 Jefferies Global Healthcare Conference - Yahoo Finance finance.yahoo.com - June 8 at 6:59 PM
	Sensorion Announces Approval in France to Initiate Proof of Concept Clinical Trial of SENS-401 for Residual Hearing Preservation During Cochlear Implantation - Yahoo Finance finance.yahoo.com - June 7 at 5:23 PM
	Aerin Medical’s RhinAer® Demonstrates Long-term Safety and Efficacy for Treatment of Chronic Rhinitis in Newly Published Two-year Study - Yahoo Finance finance.yahoo.com - June 7 at 12:22 PM
	Microbion Corporation Receives up to $2.1 million in Funding Support from the US Navy in Partnership with CUBRC, Inc. to Advance Topical Pravibismane - Yahoo Finance finance.yahoo.com - June 7 at 12:22 PM
	ASCO 2022 \| Ascentage Pharma Releases Updated Results Demonstrating the Therapeutic Potential of Alrizomadlin (APG-115) plus Pembrolizumab in Patients with Solid Tumors who Progressed on Immunotherapies - Yahoo Finance finance.yahoo.com - June 7 at 6:44 AM

Get Curis News Delivered to You Automatically

This page (NASDAQ:CRIS) was last updated on 9/28/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms